Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML by Brian J. Ball, Wenbin Xiao, Gautam Borthakur, Le Xuan Truong Nguyen, Melissa Valerio, Avanthika Venkatachalam, Guido Marcucci, Anthony S. Stein, Dung Luong Thai, David N. Cook, Kyle Chan, Sonali Persaud, Ross L. Levine, Omar Abdel-Wahab, Yinon Ben-Neriah, Eytan M. Stein

Get full text